Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule treatments for cancer, Zentalis focuses on targeted therapies for solid tumors. Its lead drug candidate, azenosertib (ZN-c3), is a WEE1 inhibitor designed to block a protein that helps cancer cells repair damaged DNA. The company is headquartered in San Diego, California.
Bought 6.46M
Sold 7.50M
Granted 57.1K
Granted 57.1K
Granted 57.1K
Granted 57.1K
Granted 57.1K
Sold 43.3K
Granted 114.2K
Sold 8.8K
Sold 3.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Walters Group +2 co-filers10% owner · 1 transaction | — | 7.05M | — | 6.46M | — |
| Goel David E. +1 co-filer10% owner · 1 transaction | — | 6.46M | — | — | 7.50M |
| Myers Scott DunsethDirector · 1 transaction | +16.9% | 395.9K | 57.1K | — | — |
| Johnson David MichaelDirector · 1 transaction | +22.8% | 307.5K | 57.1K | — | — |
| Skvarka JanDirector · 1 transaction | +27.6% | 264.3K | 57.1K | — | — |
| Walker Luke NathanielDirector · 1 transaction | +39.6% | 201.4K | 57.1K | — | — |
| Kariuki EnochDirector · 1 transaction | +41.6% | 194.5K | 57.1K | — | — |
| Vultaggio VincentPAO and PFO · 5 transactions | -22.8% | 146.5K | — | — | 43.3K |
| Campbell ShannonDirector · 1 transaction | — | 114.2K | 114.2K | — | — |
| Eastland Julia MarieCEO & President, Director · 2 transactions | -10% | 79.1K | — | — | 8.8K |
| Bruns IngmarChief Medical Officer · 2 transactions | -9% | 33.3K | — | — | 3.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -1.10M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.